Mechanism(s) Underlying Cardiovascular Effects of ARB/NEP Inhibition - Aim 2
Status:
Withdrawn
Trial end date:
2020-01-01
Target enrollment:
Participant gender:
Summary
This study tests the hypothesis that endogenous bradykinin contributes to effects of a
combined angiotensin receptor blocker/neprilysin inhibitor (LCZ696 or Entresto)
Phase:
Phase 2
Details
Lead Sponsor:
Vanderbilt University Medical Center
Treatments:
Enalapril Enalaprilat Icatibant LCZ 696 Sacubitril and valsartan sodium hydrate drug combination Valsartan